Canagliflozin
Brand name: Invokana
Canagliflozin comes in 10 pill versions in our database, in 2 strengths, from 5 manufacturers. Check the imprint to tell them apart.
Canagliflozin pill images
100 mg 5 pills
- CFZ 100 Canagliflozin 100 mg Yellow, oval, 11 mm Used for type 2 diabetes
- T 80 Canagliflozin 100 mg Yellow, capsule Used for type 2 diabetes
- 100 CA Canagliflozin 100 mg Yellow, capsule Used for type 2 diabetes
- APO CZ100 Canagliflozin 100 mg Yellow, capsule Used for type 2 diabetes
- No picture yet DIN 02425483 Canagliflozin 100 mg Invokana, Tablet, sold in Canada Used for type 2 diabetes
300 mg 5 pills
- CFZ 300 Canagliflozin 300 mg White, oval, 17 mm Used for type 2 diabetes
- T 90 Canagliflozin 300 mg White, capsule Used for type 2 diabetes
- 300 CA Canagliflozin 300 mg White, capsule Used for type 2 diabetes
- APO CZ300 Canagliflozin 300 mg White, capsule Used for type 2 diabetes
- No picture yet DIN 02425491 Canagliflozin 300 mg Invokana, Tablet, sold in Canada Used for type 2 diabetes
What is Canagliflozin used for?
Canagliflozin is used for type 2 diabetes.
- Medicine type
- Diabetes medicine (SGLT2 inhibitor)
Official uses from the US prescribing label
INVOKANA (canagliflozin) is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD).
- to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.
Limitations of Use
INVOKANA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
INVOKANA is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2. INVOKANA is likely to be ineffective in this setting based upon its mechanism of action.
From the FDA-approved label on DailyMed (published Sep 23, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.